Sugi Predict

Sugi Predict / Compounds / SCHEMBL558183

SCHEMBL558183

SCHEMBL558183

COC(=O)c1ccc(O)c(C(=O)OC(C)(C)C)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 6/20 0.59
▸ CA1 P00915 6/20 0.59
▸ CA2 P00918 6/20 0.59
▸ CA9 Q16790 6/20 0.59
▸ CA14 Q9ULX7 6/20 0.59
▸ CA7 P43166 5/20 0.59
▸ XDH P47989 2/20 0.59
▸ KDM4E B2RXH2 4/20 0.53
▸ HPGD P15428 4/20 0.53
▸ HSD17B10 Q99714 4/20 0.53
▸ LMNA P02545 3/20 0.53
▸ ALDH1A1 P00352 3/20 0.53
▸ MAPT P10636 2/20 0.53
▸ TP53 P04637 2/20 0.53
▸ ALOX15 P16050 2/20 0.53
▸ ALOX12 P18054 2/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ HTT P42858 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL403210 0.86 CA12 (0.71) CA12CA1CA2CA9CA14
SCHEMBL2874165 0.85 KDM4E (0.56) CA12CA1CA2CA9CA14
SCHEMBL3982155 0.85 EGFR (0.49) CA12CA1CA2CA9CA14
SCHEMBL15701587 0.84 NOTUM (0.48) CA12CA1CA2CA9CA14
SCHEMBL1930540 0.83 ALDH1A1 (0.55) CA12CA1CA2CA9CA14
SCHEMBL31587840 0.82 CA12 (0.45) CA12CA1CA2CA9CA14
SCHEMBL25143536 0.82 KDM4E (0.51) CA12CA1CA2CA9CA14
SCHEMBL31665103 0.82 KDM4E (0.51) CA12CA1CA2CA9CA14
SCHEMBL27440095 0.80 KDM4E (0.50) CA12CA1CA2CA9CA14
SCHEMBL29826125 0.80 CA1 (0.67) CA12CA1CA2CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11498903-B2 2-(1,1′-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases BRISTOL-MYERS SQUIBB COMPANY (US) 2022-11-15 — — US disclosed
US-20200231547-A1 2-(1,1'-BIPHENYL)-1H-BENZODIMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS APELIN AND APJ AGONISTS FOR TREATING CARDIOVASCULAR DISEASES BRISTOL MYERS SQUIBB CO (US) 2020-07-23 — — US disclosed
US-9914740-B2 Tricyclic pyrido-carboxamide derivatives as rock inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-03-13 — — US disclosed
US-9914740-B2 Tricyclic pyrido-carboxamide derivatives as rock inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-03-13 — — US disclosed
US-9914740-B2 Tricyclic pyrido-carboxamide derivatives as rock inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-03-13 — — US disclosed
EP-3016951-B1 TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-05-31 — — EP disclosed
EP-3016951-B1 TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-05-31 — — EP disclosed
US-RE46170-E1 Insulin derivatives NOVO NORDISK A/S (DK) 2016-10-04 — — US disclosed
US-RE46170-E1 Insulin derivatives NOVO NORDISK A/S (DK) 2016-10-04 — — US disclosed
US-RE46170-E1 Insulin derivatives NOVO NORDISK A/S (DK) 2016-10-04 — — US disclosed
EP-2256130-A1 Novel insulin derivatives Novo Nordisk A/S (DK) 2010-12-01 — — EP disclosed
EP-2256130-A1 Novel insulin derivatives Novo Nordisk A/S (DK) 2010-12-01 — — EP disclosed
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 — — US disclosed
US-20080076705-A1 Insulin Derivatives NOVO NORDISK A/S (DK) 2008-03-27 — — US disclosed
US-20080076705-A1 Insulin Derivatives NOVO NORDISK A/S (DK) 2008-03-27 — — US disclosed
US-20080076705-A1 Insulin Derivatives NOVO NORDISK A/S (DK) 2008-03-27 — — US disclosed
EP-1846446-A1 INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2007-10-24 — — EP disclosed
WO-2006082204-A1 INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2006-08-10 — — WO disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 — — US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 CA12 1675/4885CA1 877/4885CA2 221/4885
US-20200231547-A1 2-(1,1'-BIPHENYL)-1H-BENZODIMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS APELIN AND APJ AGONISTS FOR TREATING CARDIOVASCULAR DISEASES APLNR, AP3B1, AP2B1 CA12 4589/4885CA1 4590/4885CA2 2535/4885
US-20080076705-A1 Insulin Derivatives IAPP, INSR, GPR119 CA12 1308/4885CA1 1560/4885CA2 1665/4885
US-11498903-B2 2-(1,1′-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases APLNR, AP3B1, AP2B1 CA12 4603/4885CA1 4615/4885CA2 2589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.